-
ALSO READ
Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts
Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales
Cipla Q2 net profit up 12% at Rs 797 crore, revenue rises to Rs 5,829 crore
Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet
Biocon sells 5.4% stake in arm Syngene International for Rs 1,220 cr
-
Drug major Cipla on Wednesday reported a 7 per cent increase in its consolidated net profit to Rs 808 crore for the third quarter ended December 2022, aided by robust sales.
The Mumbai-based drug maker had reported a net profit of Rs 757 crore for the October-December period of the last fiscal.
Its total revenue from operations rose to Rs 5,810 crore for the third quarter compared to Rs 5,479 in the year-ago period, Cipla said in a regulatory filing.
For the nine months ended December 31, 2022, the company reported a net profit of Rs 2,311 crore against Rs 2,176 crore in the same period last fiscal.
Shares of the company were trading 2.73 per cent down at Rs 1,032.50 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
First Published: Wed, January 25 2023. 15:15 IST
RECOMMENDED FOR YOU